Myasthenia Gravis Quiz: A Clinical Challenge for Providers
Reviewed by: HU Medical Review Board | Last reviewed: June 2026 | Last updated: July 2026
Myasthenia gravis (MG) care is evolving fast, with FcRn blockers, complement inhibitors, and emerging B-cell and CAR-T therapies reshaping how clinicians diagnose and manage the disease. This quiz tests your knowledge of diagnosis, acute management, FcRn biology, and treatment selection.
Clinical Challenge
A patient with MG presents with impending myasthenic crisis with rapidly worsening bulbar and respiratory weakness, a falling forced vital capacity, and rising pCO₂. In addition to airway monitoring and ICU-level care, what is the most appropriate immediate immunomodulatory therapy?
Clinical Challenge
Which statement about FcRn-targeted therapy in generalized MG (gMG) is correct?
Clinical Challenge
A 34-year-old woman with MuSK-antibody-positive gMG has persistent bulbar weakness despite optimized immunotherapy. A colleague suggests switching to a complement C5 inhibitor. What is the most appropriate next step and rationale?
Clinical Challenge
Before initiating a complement C5 inhibitor for refractory AChR-positive gMG, which intervention is most critical to reduce a serious, label-warned risk?
Clinical Challenge
A 58-year-old woman with AChR-positive gMG has ongoing fatigable ptosis and intermittent dysphagia despite treatment with pyridostigmine and an FcRn inhibitor for several months. She has not previously received complement directed therapy. What is the most reasonable next step?